First NDIN-Completed Akkermansia muciniphila for Muscle Health: BiomeNrich™ POST M005
CHICAGO, March 26, 2025 /PRNewswire/ -- CJ BIO's BiomeNrich™ POST M005 is the first Akkermansia muciniphila-based ingredient to receive New Dietary Ingredient Notification (NDIN) acknowledgment from the U.S. Food and Drug Administration (FDA). This milestone confirms its safety and expands its potential in nutritional and functional food applications. ...
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Financial Performance: Strong Year-over-Year Improvement- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.- Net Loss Reduction: 71.5% year-over-year improvement. Key Product Advancements- Sugemalimab (Anti-PD-L1 mAb)- Regulatory Milestones: - China: Approved for first-line treatment of gastric/gastroesophageal junction adenocarcinoma (GC/GEJC). ...
Tigermed Reports Full Year 2024 Results
HANGZHOU, China, March 27, 2025 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). This press release is for information purposes...
DeepCare Unveils Game-Changing Dental AI Agent at IDS 2025
COLOGNE, Germany, March 27, 2025 /PRNewswire/ -- From March 25 to 29, 2025, DeepCare, a global leader in dental AI, showcases its Multimodal Dental AI Agent and newly upgraded CBCT AI features at the International Dental Show (IDS 2025) in Cologne, Germany. As the world's largest and most influential dental exhibition, IDS gathers industry leaders and experts to explore cutting-edge...
ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach
JENA, Germany, March 27, 2025 /PRNewswire/ -- ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has received National Medical Products Administration (NMPA) approval in China, marking a significant milestone in the product's global journey. ILM-Blue from DORC "ZEISS...
Celltrion’s STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 Celltrion's adalimumab-aaty was previously added to the Costco Member Prescription Program in August 2024 JERSEY CITY, N.J., March 27, 2025 /PRNewswire/ -- Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has...
Hyundai ADM Demonstrates Anti-Metastatic Effect of ‘PenetriumTM’ in TNBC Preclinical Study
– Simultaneous treatment of primary and metastatic tumors by eliminating pseudo-resistance SEOUL, South Korea, March 27, 2025 /PRNewswire/ -- Hyundai ADM Bio (KOSDAQ symbol 187660) announced on the 24th that its first-in-class pseudo-resistance-targeting agent, PenetriumTM, showed significant anti-metastatic efficacy in a preclinical study on triple-negative breast cancer (TNBC). Detailed results will be presented...
FlocCare secures US$500K to drive healthcare awareness and patient engagement with Gen AI
SINGAPORE, March 27, 2025 /PRNewswire/ -- Singapore-based B2B healthcare AI platform FlocCare Pte. Ltd. has just raised US$500K, with backing from DTVP, SDTA Ventures and prominent healthcare angel investors in Singapore. This funding will fuel FlocCare's expansion to more disease specific gen AI models to empower clinics and hospitals for preventative health for their patients: Adding cardio-vascular, CKD, Women's Health...
Docquity and Novartis Partner to Tackle Retinal Health Challenges in Malaysia
The multi-year collaboration leverages Docquity's Awareness to Advocacy (A2A) Program to expand retinal health education amongst thousands of HCPs and widen access to retinal health products With 81.5% of Southeast Asian doctors participating in both digital and in-person learning (Docquity Pulse Check), the initiative's omnichannel approach strengthens engagements with ophthalmologists and medical...
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology...
